Balt

What Balt does

Balt is a French-headquartered medical device company specializing in interventional neuroradiology (INR) devices used to treat strokes and aneurysms. Founded in 1977, the company pioneered one of the first neurovascular intervention devices and has since built what it describes as the world's broadest portfolio of medical devices for ischemic and hemorrhagic stroke treatment, including embolization coils, flow diverters such as Silk Vista, and thrombectomy devices. Balt has recently extended into the peripheral vascular space with dedicated peripheral embolization products.

The company monetizes through direct hardware sales of medical devices to hospitals and ambulatory surgical centers, delivered through enterprise field sales channels across more than 70 countries. Balt operates from its Paris-area headquarters and from a growing U.S. manufacturing and research footprint in Irvine, California, where it opened an 85,000-square-foot second facility on May 12, 2026 as part of a $400 million multi-year U.S. investment strategy through 2030. Clinical credibility is anchored by publication of the STEM trial results in the New England Journal of Medicine.

Corporate structure comprises Balt SAS as the French parent and Balt USA LLC as the U.S. operating subsidiary, with wholly-owned Blockade Medical contributing neurovascular device IP. Leadership includes Pascal Girin as President and CEO, Léopold Plowiecki as Founder, Dave Ferrera as CTO, and Emeric Domergue as Deputy CFO. The company is privately held with no public listing disclosed.

Name

Balt

Legal name

Balt Group

Website

https://balt.fr

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Balt is a French-founded medical device company that designs, manufactures, and sells interventional neuroradiology devices—including embolization coils, flow diverters, and thrombectomy products—for treating ischemic and hemorrhagic strokes and aneurysms, selling to hospitals and ambulatory surgical centers across 70+ countries.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHAFAJ

Thrombectomy, Embolic Protection & Stroke Intervention Devices

Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

• Neurovascular medical devices
• Stroke treatment devices
• Embolization coils
• Flow diverters
• Peripheral embolization

Headquarters

HQ city

Montmorency

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Medical Device Sales: Sale of neurovascular medical devices including stroke treatment devices and peripheral embolization products to hospitals and healthcare facilities globally

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Balt designs, manufactures, and sells neurovascular medical devices used by hospitals and ambulatory surgical centers to treat ischemic and hemorrhagic stroke, cerebral aneurysms, and peripheral embolization conditions. Its portfolio includes embolization coils, occlusion devices, flow diverters such as Silk Vista, and thrombectomy devices, with growing presence in the peripheral vascular space.

Product overview

Balt is a global neurovascular medical device company offering the world's broadest portfolio of medical devices for ischemic and hemorrhagic stroke treatment, as well as dedicated products to address peripheral embolization. Founded in France in 1977, the company operates in more than 70 countries. Balt's product portfolio includes devices like Silk Vista for neurovascular embolization, serving both ischemic and hemorrhagic stroke applications. The company has recently expanded into the peripheral vascular space while maintaining its leadership in stroke treatment technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Silk Vista Neurovascular embolization device used by hospitals and interventional neuroradiologists for the treatment of ischemic and hemorrhagic stroke, part of Balt's broad portfolio of minimally invasive neurovascular medical devices.
• Neurovascular Embolization Coils and Occlusion Devices Coil transcatheter embolization and occlusion devices used by hospitals for the minimally invasive treatment of neurovascular conditions including stroke and cerebral aneurysms.
• Peripheral Embolization Products

Quantifiable outcome

• STEM trial results published in New England Journal of Medicine

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Blockade MedicalacquisitionStrategic or Co-development Partner · 1 January 2021Balt acquired Blockade Medical, a neurovascular and stroke treatment device company founded by David Ferrera. This acquisition strengthened Balt's portfolio of neurovascular devices for stroke treatment.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Stryker (Neurovascular): Stryker's Neurovascular division (acquired via the $1.4B acquisition of Concentric Medical, Sage, and Penumbra-adjacent assets) is one of the largest direct competitors in stroke intervention devices. Overlapping product lines include stent retrievers, aspiration catheters, and flow diverters sold into the same hospital neurointerventional suites.
• Medtronic (Neurovascular): Medtronic's Neurovascular operating unit competes head-to-head with Balt in coils, flow diverters (Pipeline), and stent retrievers. As a global medtech incumbent, Medtronic competes with Balt's Silk Vista and broader portfolio in the same hospital channels.
• Penumbra Inc. Penumbra is a U.S.-based direct competitor specializing in aspiration thrombectomy systems for stroke (Penumbra System, RED catheters) and peripheral vascular. Penumbra competes with Balt in both ischemic stroke and peripheral embolization markets.
• Cerenovus (Johnson & Johnson): Cerenovus, J&J's neurovascular business, offers coils, flow diverters, and stroke intervention devices. As a deep-pocketed incumbent, Cerenovus competes with Balt across its full neurovascular portfolio in U.S. and global hospital channels.
• MicroPort Scientific (Neurovascular): MicroPort acquired Rapid Medical and operates a neurovascular portfolio competing with Balt in flow diverters and stroke devices. MicroPort's broader geographic footprint in EMEA and APAC overlaps with Balt's 70+ country presence.
• Rapid Medical: Rapid Medical develops adjustable neurovascular devices (stent retrievers, flow diverters). Acquired by MicroPort, Rapid Medical competes directly with Balt in the same clinical use cases for stroke and aneurysm treatment.
• Phenox GmbH: Phenox is a European-headquartered neurovascular device company with flow diverters (p64, p48MW), coils, and stent retrievers. Comparable in scale and product breadth to Balt's neurovascular portfolio, primarily serving EMEA and select global markets.

Broad incumbents

• Terumo (Neurovascular): Terumo is a global medical device conglomerate with neurovascular products through its Terumo Neuro division (acquired from MicroVention). Competes with Balt across coils, flow diverters, and access devices as part of a much broader medical device portfolio.

Emerging players

• Inari Medical: Inari Medical specializes in venous thromboembolism and peripheral vascular intervention devices. As Balt expands into peripheral embolization, Inari represents an emerging competitor in the adjacent peripheral vascular space.
• InspireMD: InspireMD develops neurovascular and carotid artery stents (CGuard). An emerging player with partial product overlap with Balt's neurovascular portfolio, focused on stroke prevention rather than acute intervention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/balt_group
• LinkedInlinkedin.com/company/balt-group
• Instagraminstagram.com/balt_group_?utm_medium=copy_link

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Balt